These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2155998)

  • 1. Characterization of neutralizing monoclonal antibodies to murine cytomegalovirus.
    Farrell HE; Shellam GR
    J Gen Virol; 1990 Mar; 71 ( Pt 3)():655-64. PubMed ID: 2155998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies.
    Farrell HE; Shellam GR
    J Gen Virol; 1991 Jan; 72 ( Pt 1)():149-56. PubMed ID: 1846643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A murine cytomegalovirus-neutralizing monoclonal antibody exhibits autoreactivity and induces tissue damage in vivo.
    Chapman AJ; Farrell HE; Thomas JA; Papadimitriou JM; Garlepp MJ; Scalzo AA; Shellam GR
    Immunology; 1994 Mar; 81(3):435-43. PubMed ID: 7515848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal IgM antibodies from cytomegalovirus-infected mice recognize the GlcNAc-containing receptor determinant of murine CMV as well as neutralizing anti-CMV IgG antibodies.
    Ravindranath RM; Graves MC
    Virology; 1992 May; 188(1):143-51. PubMed ID: 1373551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice.
    Lawson CM; Grundy JE; Shellam GR
    J Gen Virol; 1988 Aug; 69 ( Pt 8)():1987-98. PubMed ID: 2841411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity.
    Lawson CM; O'Donoghue HL; Farrell HE; Shellam GR; Reed WD
    Immunology; 1991 Mar; 72(3):426-33. PubMed ID: 1851134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoblot analysis of the antibody response to murine cytomegalovirus in genetically resistant and susceptible mice.
    Farrell HE; Shellam GR
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2573-86. PubMed ID: 2552004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoclonal antibodies neutralizing human cytomegalovirus.
    Masuho Y; Matsumoto Y; Sugano T; Fujinaga S; Minamishima Y
    J Gen Virol; 1987 May; 68 ( Pt 5)():1457-61. PubMed ID: 2437245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of antigenicity and genetic variation of glycoprotein B of murine cytomegalovirus.
    Xu J; Lyons PA; Carter MD; Booth TW; Davis-Poynter NJ; Shellam GR; Scalzo AA
    J Gen Virol; 1996 Jan; 77 ( Pt 1)():49-59. PubMed ID: 8558128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
    Christensen ND; Reed CA; Cladel NM
    Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of monoclonal antibodies to spring viraemia of carp virus.
    Chen ZY; Liu H; Li ZQ; Zhang QY
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):266-76. PubMed ID: 18378003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
    Stave JW; Card JL; Morgan DO
    J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies.
    Czerny CP; Mahnel H
    J Gen Virol; 1990 Oct; 71 ( Pt 10)():2341-52. PubMed ID: 1700065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis.
    Lawson CM; O'Donoghue HL; Reed WD
    Immunology; 1992 Mar; 75(3):513-9. PubMed ID: 1315309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies directed to two groups of viral proteins neutralize human cytomegalovirus in vitro.
    Furlini G; Gonczol E; Szokan G; Ianacone J; Plotkin SA
    Hybridoma; 1987 Jun; 6(3):321-6. PubMed ID: 2439441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of interferon to protect virus-infected cells against lysis by natural killer (NK) cells correlates with NK cell-mediated antiviral effects in vivo.
    Bukowski JF; Welsh RM
    J Immunol; 1985 Nov; 135(5):3537-41. PubMed ID: 2413125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and processing of a 22-26K murine cytomegalovirus glycoprotein recognized by a neutralizing monoclonal antibody.
    Loh LC
    Virology; 1989 Apr; 169(2):474-8. PubMed ID: 2539702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift.
    Lambkin R; McLain L; Jones SE; Aldridge SL; Dimmock NJ
    J Gen Virol; 1994 Dec; 75 ( Pt 12)():3493-502. PubMed ID: 7527838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2.
    Barnett PV; Rowlands DJ; Parry NR
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1295-302. PubMed ID: 8393073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.